Aims: Recombinant PEGylated human granulocyte colony-stimulating factor (pegfilgrastim) is indicated for the reduction of chemotherapy-induced neutropenia and prevention of febrile neutropenia. Biosimilar pegfilgrastim is expected to reduce the financial burden of this complication of chemotherapy. The aim of this study was to demonstrate biosimilarity between Sandoz biosimilar pegfilgrastim and its US-and EU-approved reference biologics.
| INTRODUCTION
Unmet medical needs in providing access to biologics can in part be addressed by the development and availability of biosimilars, which improve availability of well-established therapeutic and supportive care. 1 The affordability and sustainability of cancer care is expected to be enhanced by the successful uptake of biosimilar medicines. 2 A biosimilar is a biological medicine shown to be highly similar to another already approved biological medicine (the reference biologic). 3 Biosimilar clinical development programmes differ from traditional reference biologic development in that Phase I studies demonstrating pharmacokinetic (PK) and pharmacodynamic (PD) similarity to the reference biologic in healthy volunteers or patients play a pivotal role. 4 To gain marketing authorization, a biosimilar must demonstrate similarity in terms of physicochemical characteristics and biological activity, as well as similar PK, PD, efficacy and safety in humans compared with the reference biologic via the totality of evidence approach. 3, [5] [6] [7] If the biosimilar is shown to have similar efficacy and safety to its reference biologic in one indication, it may be granted authorization in all of the indications held by the reference biologic through the scientific principle of extrapolation, provided there is scientific justification. 5, 8 For a range of cancer types (such as pancreatic, gastric, and metastatic breast cancer) myelosuppressive chemotherapy remains a key therapeutic strategy. 9, 10 Frequently, patients undergoing myelosuppressive chemotherapy experience neutropenic complications, including life-threatening febrile neutropenia. Pegfilgrastim (Neulasta, Amgen, Thousand Oaks, CA, USA) is a long-acting form of the recombinant methionyl human granulocyte colony-stimulating factor (rG-CSF) filgrastim covalently conjugated to polyethylene glycol (PEG).
Pegfilgrastim, also called pegylated rG-CSF, is indicated in adult patients treated with cytotoxic chemotherapy for malignancies, in order to reduce the duration of neutropenia and incidence of febrile neutropenia. 11, 12 Biosimilars of pegfilgrastim have received marketing authorization Using state-of-the-art analytical procedures, the structural, physicochemical and functional characteristics of Sandoz biosimilar pegfilgrastim have been demonstrated to be comparable to those of reference pegfilgrastim, referred to as the reference biologic in this article. An analytical bridge between European (EU-) and US-approved reference products and Sandoz biosimilar pegfilgrastim has also been performed, with analytical similarity established.
To demonstrate biosimilarity of Sandoz biosimilar pegfilgrastim to both US-reference biologic 12 as requested by FDA 13 and EUreference biologics 11 as requested by the European Medicines Agency, 14 a 3-way clinical Phase I study is required to confirm PK and PD profile similarity of the 3 biologics after a single dose subcutaneous administration in humans.
High interindividual PK variability has previously been reported for pegfilgrastim, [15] [16] [17] and was also recognized in the previous 2-arm clinical study conducted with Sandoz biosimilar pegfilgrastim. 18 The new 2018 European Medicines Agency Guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating factor (rG-CSF) clearly states that the intrasubject variability of pegfilgrastim PK properties is considerably lower than the intersubject variability. 19 To circumvent this high interindividual PK variability, the study was designed as a 3-way cross-over study, so that variability in treatment differences could be reduced by having within-subject comparisons.
The aim of the article is to present and discuss results of the study which demonstrated PK/PD similarity, similar safety, and similar immunogenicity between Sandoz biosimilar pegfilgrastim and the approved US-and EU-reference biologics in healthy subjects, as well as similarity between US and EU references.
| METHODS

| Design
This was a Phase I, randomized, double-blind, single-dose, 3-treatment-period, 6-sequence cross-over, multicentre study designed to evaluate the PK, PD, safety and immunogenicity of Sandoz biosimilar pegfilgrastim and compare them to the US-and EUreference biologics in 576 healthy male and female subjects, aged 18-55 years ( Figure S1 ). The marketed dose of the pegfilgrastim reference product, 6 mg/0.6 mL in a prefilled syringe, was used in this
What is already known about this subject
• Sandoz biosimilar pegfilgrastim has been shown to be highly similar to EU-reference; however, similarity of pharmacokinetics and pharmacodynamics between Sandoz biosimilar and US-, and between US-and EUreference pegfilgrastim has not previously been established.
What this study adds
• This large study demonstrates similarity for pharmacokinetics and pharmacodynamics and shows no meaningful differences in safety and immunogenicity between Sandoz biosimilar and US-and EU-reference pegfilgrastim, which provides bridging data for previous efficacy and safety studies where only EU-reference biologic has been used. study. The study was performed in 1 site in the Netherlands and 5 sites across the USA. Subjects eligible for inclusion in this trial had to fulfil all of the following key criteria by Day −1 of Treatment Period I: healthy subjects aged between 18-55 years; physically and mentally healthy, as determined by medical history, physical examination and safety laboratory assessments; weight: ≥60 kg; body mass index 19.0-30.0 kg/m 2 ; and absolute neutrophil count (ANC) of 2-7 × 10 9 cells/L. Subjects fulfilling any of the following criteria at screening and baseline (Day −1) of Treatment Period I were not eligible for inclusion in this study: known previous exposure to filgrastim, pegfilgrastim, G-CSF or any analogue of these; known hypersensitivity to the study drug or any of its constituents, hypersensitivity to Escherichia coli derived proteins; history of an acute severe allergic reaction (e.g. anaphylaxis, delayed hypersensitivity reaction); history and/or current evidence of moderate-to-severe allergy requiring medical treatment; history and/or current evidence of clinically significant latex allergy; positive anti-drug antibody (ADA) for pegfilgrastim and/or filgrastim and/or PEG at screening; history or current evidence of any clinically significant finding that, in the opinion of the investigator, would preclude inclusion in the study; history or current evidence of any clinically significant condition that might interfere with the distribution, metabolism, or excretion of any of the investigational drugs.
During the study, concomitant medication used to treat adverse events, hormonal contraceptives, hormone replacement therapy were allowed. Vitamins, minerals and nutritional supplements were permitted as per investigator's discretion. Use of any medications/nondrug therapies subsequent to screening was monitored and documented at every patient visit. The study duration per subject was at least 25 weeks. After screening, volunteers were randomized 1:1:1:1:1:1 to 1 of 6 treatment sequences ( Figure S1 ).
In each treatment period, each volunteer received a single subcutaneous injection of 6 mg/0.6 mL from a prefilled syringe of either Sandoz biosimilar pegfilgrastim, EU-reference or US-reference biologics.
Administration of the study drug was always performed in the morning between 8 am and 11 am on Day 1 of each treatment period and PK/PD samples were collected at fixed, predefined time points (with a limited window allowance) following the study drug administration. 
| Bioanalytical methods for PK, PD and immunogenicity
Pegfilgrastim serum concentrations and ADAs from healthy subjects were quantified/detected in the Sandoz laboratory (Oberhaching, Germany) using fully validated immunoassays.
Pegfilgrastim drug concentrations were determined using a sandwich enzyme-linked immunosorbent assay consisting of a capture anti-filgrastim antibody and a horseradish peroxidase-labelled antifilgrastim detection antibody. Absorption was read photometrically, which is directly proportional to the amount of conjugate bound to the antibody complex.
The detection of ADAs against pegfilgrastim was performed using a sandwich enzyme-linked immunosorbent assay. In brief, antipegfilgrastim antibodies bind to a biotinylated pegfilgrastim immobilized on a streptavidin-coated plate and to a digoxigeninlabelled pegfilgrastim. Following an initial screening of all serum samples, positive samples were further analysed in a confirmatory assay.
Confirmed positive samples were then further characterized by determination of the antibody titre.
Neutralizing antibodies were determined with a cell-based assay using NFS60 cells. NFS60 cell proliferation is stimulated by the addition of pegfilgrastim. In the presence of neutralizing antibodies (NAbs) against pegfilgrastim, the growth factor is bound and cell proliferation is inhibited. The number of viable cells was quantified with CellTiter-Glo. To differentiate between neutralizing anti-pegfilgrastim antibodies and unspecific cytotoxicity, serum samples that induced a reduced cell proliferation were subsequently analysed.
For both PK and ADA assays, the coefficients of variation (%) of the mean OD of a duplicate determination had to be ≤20%. At the upper and lower limits of quantification (LOQs), a coefficient of variation of ≤25% was acceptable. For the pegfilgrastim drug concentrations, the calibration ranged from 1.5 (lower LOQ) to 48 ng/mL (upper LOQ). The limit of detection of the ADA assay was validated at 13 ng/mL. ANCs were measured in local clinical laboratories using standardized flow cytometry-based routine haematology methods.
| Objective, primary and secondary endpoints
This Phase I study aimed to confirm that Sandoz biosimilar pegfilgrastim is similar to US-and EU-reference biologics in terms of PK, PD, safety and immunogenicity in healthy volunteers. The follow- 
| Statistics
Data from a previous Phase I cross-over study made an assumption of 14, 14 and 10% difference in GM of AUC 0−inf , AUC 0−last and C max between Sandoz biosimilar pegfilgrastim and reference biologics. 20 The estimated difference for PD was 5% for both AUEC and E max .
Since the study duration of ≥25 weeks is relatively long for a PK/PD study, and it was assumed that most subjects would experience pain as an adverse event (AE; bone pain, back pain, headache, and myalgia), there was a high risk of volunteers dropping out with time. The dropout rate was estimated to be 25%, and included subjects lost to follow-up and subjects potentially excluded from the full analysis set for other reasons (e.g. major protocol deviations). Based on the above criteria, the estimated variability and correlation among the coprimary endpoints, a total of 576 randomized healthy male and female subjects were planned to be enrolled to achieve at least 432 evaluable subjects (with 72 per sequence). This resulted in an overall power of 90% to conclude that similarity would be given for all co-primary endpoints in all pairwise comparisons (biosimilar vs US-reference, biosimilar vs EU-reference, US-reference vs EU-reference). PK parameters of pegfilgrastim and PD parameters deriving from ANC were calculated using noncompartmental analysis with Phoenix WinNonLin (Version 8.0).
For the analyses of the primary endpoints, analyses of variance were performed on the natural logarithm transformed primary PK parameters AUC 0-inf , AUC 0-last and C max , and primary PD parameters ANC AUEC 0-last and E max , separately. The mixed effect ANOVA model included treatment, sequence and period as fixed effects and subject nested within sequence as a random effect. The analyses were performed using PROC MIXED in SAS version 9.4. Descriptive analyses were provided for each PK and PD parameter, safety and immunogenicity endpoints.
| Analysis sets
The safety analysis set (SAF) includes all randomized subjects who received the investigational medicinal product (IMP) at least once.
Subjects were analysed according to the treatment they received. The full analysis sets for PK (FAS-PK) and PD (FAS-PD), included all subjects who received study drugs and who had at least 1 of the evaluable PK or PD parameters defined as primary endpoints in at least 2 periods without a major protocol violation. Primary PK and PD analyses in the study were based on FAS-PK and FAS-PD, respectively. 
| Safety
TEAEs were defined as AEs with a date of onset occurring on or after the first study drug administration until 4 weeks after last study drug administration, or conditions present prior to the first study drug administration that increased in severity, changed from being not suspected to being suspected of study drug relationship, or developed into serious AEs (SAEs) after study drug administration. completed Period III (Figure 1 ).
In the SAF (n = 577), subject demographic characteristics were well balanced across the 6 treatment sequence groups at baseline (Table 1 ). In the FAS-PK (n = 496), FAS-PD (n = 496) and ADAnegative (n = 479) analysis sets, subject demographics were also balanced across the treatment sequence groups at baseline. Overall, 130/577 subjects (22.5%) discontinued the study prematurely, which was below the assumed drop-out rate of 25% used to estimate the required study sample size. Subjects who received study drug in only Period I (n = 81) were excluded from the FAS-PK and the FAS-PD due to absence of results for the primary PK/PD parameters in subsequent treatment periods, leading to lack of intraindividual comparison.
| PK
Following subcutaneous administration of a single dose of 6 mg, pegfilgrastim concentrations were increasing up to about 12 hours where a plateau was reached, followed by a slight decrease from 36 to 48 hours and a more rapid decline until the last measurable concentrations (Figure 2A ). In the 3 treatment periods combined, primary PK parameter (AUC 0-inf , AUC 0-last and C max ) GM values were comparable among the 3 biologics groups (Table 2) , with ratios of point estimates for the comparisons, i.e. between 0.98 and 1.07 for AUC 0-inf , between 0.98 and 1.06 for AUC 0-last , and between 0.98 and 1.05 for C max . For each pairwise comparison, the 90% CIs of the GM ratios for AUC 0-inf , AUC 0-last and C max were all contained within the predefined PK similarity margins of 0.80-1.25 ( Figure 3A) . The values of the secondary PK parameters t max and t 1/2 were comparable for Sandoz biosimilar, US-reference, and EU-reference biologics ( Table 2 ). Median t max was 12 hours in the 3 treatment groups, and GM t 1/2 was similar among the 3 biologics at~17 hours.
| PD
Following subcutaneous administration of a single dose of 6 mg, neutrophil counts were increasing up to 60 hours followed by a decrease with a return to initial baseline values at around 336 hours ( Figure 2B ). In the 3 treatment periods combined, primary PD parameter (AUEC 0-last and E max ) GM values were comparable among the 3 biologics groups (Table 2) , with ratios of point estimates for the comparisons at 1.00 for AUEC 0-last and 1.00-1.01 for E max . For each pairwise comparison, the 90% CIs for the ratios of GM for the primary PD parameters AUEC 0-last and E max were all contained within the predefined PD similarity margins of 0.80-1.25
( Figure 3B) . The values of the secondary PD parameter t max,E were 
| Safety
| Adverse events
The safety profile of Sandoz biosimilar pegfilgrastim was similar to the safety profiles of the US-and EU-reference biologics (Table S1 ). The incidences and patterns of TEAEs were similar between the 3 biologics. The 5 most common TEAEs reported by subjects were headache, back pain, bone pain, myalgia, and pain in extremity. The most frequently affected system organ class was musculoskeletal and connective tissue disorders followed by nervous system disorders. Local study drug tolerance was good and similar in all treatment groups.
The incidence of injection site reactions was low and similar in all groups. There was a tendency for the incidences of TEAEs to decrease over the course of the study. TEAEs with a suspected causal relationship to study drug are presented by system organ class, preferred term and treatment group in Table 3 .
A total of 11 subjects discontinued the study prematurely due For 1 subject in the biosimilar group, no AUC 0-inf , AUC 0-last , t 1/2 , nor PD data could be obtained in Period III; b For 1 subject in the EU-reference group, no AUC 0-inf nor t 1/2 could be obtained in Period II. For 1 subject in the US-reference group and 1 subject in the EU-reference group, no AUEC 0-last could be obtained in Period II; c Baseline corrected ANC values. ANC, absolute neutrophil count; AUC 0-inf , area under the plasma concentration-time curve from time of dosing and extrapolated to infinity; AUC 0-last , area under the plasma concentration-time curve to the last measurable concentration; AUEC 0-last , area under the effect curve measured from the time of dosing to the last measurable concentration; CI, confidence interval; C max , maximum plasma concentration; E max , maximum neutrophil count measured following administration of the study medication; FAS, full analysis set; geo CV%, coefficient of variation of the geometric mean in percent; GM, geometric mean; max, maximum; min, minimum; n, total number of subjects in each treatment group; PD, pharmacodynamic; PK, pharmacokinetic; t ½ , apparent elimination half-life; t max , time to the maximum observed serum concentration; t max,E , time to the maximum effect attributable to the therapy under investigation.
| Immunogenicity
The incidence of ADAs was low and similar across all treatment groups 
| DISCUSSION
This large Phase I study achieved its primary objectives and demonstrated the PK/PD similarity of Sandoz biosimilar pegfilgrastim to both the US-and EU-reference biologics. No meaningful differences in safety, local tolerability or immunogenicity were identified between the 3 biologics. The study results also demonstrated PK/PD similarity between US-reference and EU-reference biologics, providing the PK and PD component of the scientific bridge between both biologics, allowing consideration of the results of the efficacy safety trials performed with the EU-reference biologic as comparator. 18, 20, 21 PK similarity was demonstrated between Sandoz biosimilar and US-reference pegfilgrastim, Sandoz biosimilar and EU-reference pegfilgrastim, and US-reference and EU-reference pegfilgrastim for the primary PK parameters AUC 0-inf , AUC 0-last , and C max , as the 90% CIs for the GM ratios of all 3 comparisons were contained within the predefined PK similarity margins (0.80-1.25). The values of the secondary PK parameters t max and t 1/2 were consistent across the 3 treatment The PD marker ANC is a clinically relevant surrogate marker of efficacy in clinical practice. 22, 23 To account for the circadian variability in ANC as described by Ackermann et al., 24 the study medication was administered at a fixed, predefined time window for all participants in the study (see design section). Time points for PD blood sampling followed a schema with fixed, prespecified time points (with a limited window allowance) following the study drug administration. Therefore, the circadian variability in blood ANC is expected to be equally distributed between subjects and treatment sequences in the study.
Altogether, the equivalent PD profiles support the clinical equivalence shown in the confirmatory efficacy and safety studies of Sandoz biosimilar pegfilgrastim and the EU-reference biologic in patients with breast cancer. 25 Although the study was not designed nor powered to detect sexrelated differences, a posthoc subgroup analysis by sex was performed and showed no significant impact on the study outcome. However, higher variation in systemic drug exposure was observed in females,
an observation confirmed in recently published European Medicines
Agency draft guidance on rG-CSF products. 19 The 3 biologics are also highly similar in terms of safety, as incidences and patterns of TEAEs were similar across all treatment groups. The most frequently reported TEAE was headache, followed by back pain, bone pain, myalgia and pain in extremity, all of which were reported with frequencies >10% across the treatment groups.
All other TEAEs were reported with frequencies <10% by subjects in a treatment group. Particularly, the most frequently reported TEAEs (bone pain, myalgia and back pain) are consistent with the known safety profile of pegfilgrastim, commonly reported in the pegfilgrastim US prescribing information (bone pain and pain in extremity) and likely based on the mode of action of the drug.
The incidence of treatment-emergent SAEs was numerically slightly higher with the Sandoz biosimilar compared with US-and EU-T A B L E 3 Incidence of most frequent (≥3% of subjects in any treatment group) TEAEs related to study drug by system organ class and preferred term (SAF) Numbers and proportions of subjects with confirmed positive ADAs were similar across the 3 biologics, and primary PK and PD parameters were comparable across the 3 biologics in ADA-positive and ADA-negative subjects. Most of the ADAs were directed against the PEGylated part of the molecule, as already noted by others. 19 This may be explained by exposure to widely used PEG as well as PEG derivatives in pharmaceutical and cosmetic products.
The similar PK and PD values across all 3 biologics groups suggest that ADA positivity does not have any measurable or clinically meaningful impact on PK or PD in any of the treatment groups. The overall numbers of subjects with newly confirmed positive ADA results decreased with the duration of subject study participation in all groups. The incidence of TEAEs and study drug related TEAEs in ADA-positive subjects was similar across all groups and was lower in ADA-positive subjects than in the overall SAF population, given the limitations of the comparison.
Three subjects developed NAbs in the first period (one after biosimilar administration and 2 after EU-reference biologic administration), but no NAbs were detected in subsequent testing. All subjects with ADAs, and in particular those with NAbs, were closely examined and it was concluded that the induced ADAs did not have any clinical relevance in terms of PK, PD or safety of the 3 study biologics. Limitations of this comparison include that ADAs for individual subjects varied across treatment periods and treatment groups, high interindividual variability, and small number of subjects with confirmed positive ADAs as compared to the overall SAF population. Observation periods between the SAF population and the ADA-positive set were also different, as only TEAEs occurring after the detection of ADAs were taken into consideration in the ADA-positive set for the TEAE analysis of the 2 analysis sets, which may have biased incidence rates.
The findings of the current study are consistent with those of the Phase I PK/PD study that compared Sandoz biosimilar with the EUreference biologic exclusively 18 and with other Phase I studies comparing biosimilar pegfilgrastim medicines with the reference biologic (Neulasta). This includes published Phase I studies demonstrating similar PK/PD, safety, and immunogenicity between reference biologic and Cinfa Biotech biosimilar pegfilgrastim (B12019/Pelmeg), 26, 27 Accord Healthcare biosimilar pegfilgrastim (INTP5/Pelgraz), 28, 29 and
Mylan biosimilar pegfilgrastim (MYL-1401H/Fulphila). 30 Crossover designs were used to compare the biosimilar of pegfilgrastim to both EU-and US-reference biologics. 29 In summary, the primary objectives of this study were met, as PK and PD biosimilarity of Sandoz biosimilar pegfilgrastim with USand EU-reference biologics was achieved. Similarity was also demonstrated between the US-and EU-reference biologics, providing the PK and PD components of the scientific bridge between both biologics, allowing consideration of the results of the efficacy safety trials 20, 21 where Sandoz biosimilar pegfilgrastim was compared to only one of the 2 reference biologics. Secondary PK and PD parameter values were also close between Sandoz biosimilar pegfilgrastim, US-and EU-reference biologics, and no clinically meaningful differences were observed regarding safety and local tolerance among the treatment groups. The incidence of ADAs was similar across the treatment groups and ADAs had no impact on PK, PD or safety. In conclusion, Sandoz pegfilgrastim is biosimilar to US-and EUreference biologics.
